- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04262479
Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes (GADinLADA)
A Pilot Study on Safety, Feasibility and Insulin-promotion by Intra-inguinal Lymph Node Injections of Glutamic Acid Decarboxylase (GAD) in Patients With LADA Type of Diabetes
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent by the patient.
- Diagnosis of LADA and diabetes debut within the last 18 months before inclusion. LADA should be defined by the criteria of age ≥30 years at the onset of diabetes, anti-GAD positivity and no clinical need for permanent insulin treatment during the first 3 months after the diagnosis of diabetes.
- Fasting C-peptid levels ≥ 0.3 nmol/l
- High GADA titers (>190 U/ml)
- Patients must be insulin independent at baseline by clinical judgement and C-peptide criteria
- Antidiabetic medication in the form of metformin is acceptable for inclusion as well as medications not mentioned under exclusion criteria
- Females must agree to avoid pregnancy, and must have a negative urine pregnancy test.
Patients of childbearing potential must agree to use adequate contraception, until one (1) year after the last administration of GAD-alum. Adequate contraception is as follows:
For females of childbearing potential:
- oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable, or implanted hormonal contraceptives
- combined (estrogen and progestogen containing)
- oral, intravaginal or transdermal progesterone hormonal contraception associated with inhibition of ovulation
- intrauterine device
- intrauterine hormone-releasing system (for example, progestin-releasing coil)
- bilateral tubal occlusion
- vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate)
- male partner using condom
- abstinence from heterosexual intercourse
For males of childbearing potential:
- condom (male)
- abstinence from heterosexual intercourse
Exclusion Criteria:
- Current or previous treatment with immunosuppressant therapy (topical or inhaled steroids are accepted)
- Continuous treatment with anti-inflammatory drug (sporadic treatment e.g. because of headache or in connection with fever a few days will be accepted)
- Systemic treatment with glucocorticoids
- Treatment with any vaccine, including influenza vaccine, within 1 month prior to planned first study drug dose or planned treatment with any vaccine up to 1 month after the last injection with study drug
- Antidiabetic medication (metformin excepted)
- Significantly abnormal hematology results at screening (i.e. anemia with hemoglobin < 12 g/L).
- A history of epilepsy, head trauma or cerebrovascular accident, or clinical features of continuous motor unit activity in proximal muscles
- Clinically significant history of acute reaction to vaccines in the past.
- Renal disease (as defined by serum creatinine >150 µmol/l)
- Serious cardiovascular events (myocardial infarction, stroke) within the last year preceding recruitment.
- Participation in other clinical trials with a new chemical entity within the previous 3 months
- A history of alcohol or drug abuse
- Known HIV or hepatitis
- Presence of associated serious disease or condition, including active skin infections that preclude intralymphatic injection, which in the opinion of the investigator makes the patient non-eligible for the study
- Other serious chronic disease as judged by investigator.
- Females who are lactating, are pregnant or intend to become pregnant.
- Inability or unwillingness to comply with the provisions of this protocol
- Deemed by the investigator not being able to follow instructions and/or follow the study protocol
- Treatment any other supplementation of with vitamin D, marketed or not, or unwilling to abstain from such medication during the trial 120 days daily intake of Divisun (non-investigational medicinal product)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GAD-vaccination with vitamin D suppletion
Each study participant will receive 3 injections of 4 µg GAD-alum (Diamyd). The first, second and third injection will be one month apart. Vitamin D (Divisun 2000 IE) will be given from one month before the first injection of GAD-alum until one month after the third injection (120 days in total). |
3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart.
Supplier Diamyd Medical AB in Stockholm, Sweden
Other Names:
1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90.
Supplier Meda, Solna, Sweden
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
injection site skin reactions
Time Frame: 1 hour
|
skin reactions 1 hour post injection vs. before injection
|
1 hour
|
Occurrence of adverse events (AEs)
Time Frame: summarized at 5 months
|
continuously monitored and registered
|
summarized at 5 months
|
Occurrence of adverse events (AEs)
Time Frame: summarized at 12 months
|
continuously monitored and registered
|
summarized at 12 months
|
GAD65A titer in serum
Time Frame: at 5 months
|
concentration in serum after the first injection vs baseline
|
at 5 months
|
GAD65A titer in serum
Time Frame: at 12 months
|
concentration in serum after the first injection vs baseline
|
at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin secretion
Time Frame: 5 months after first injection
|
measured by glucagon- and MMTT stimulated C-peptide
|
5 months after first injection
|
insulin secretion
Time Frame: 12 months after first injection
|
measured by glucagon- and MMTT stimulated C-peptide
|
12 months after first injection
|
Change in HbA1c
Time Frame: from baseline to 5 and 12 months after the first injection
|
from baseline to 5 and 12 months after the first injection
|
|
Change in fasting glucose
Time Frame: from baseline to 5 and 12 months after the first injection
|
from baseline to 5 and 12 months after the first injection
|
|
Change in Fasting C-peptide
Time Frame: between baseline and 5 and 12 months after the first injection
|
between baseline and 5 and 12 months after the first injection
|
|
Change in maximum C-peptide during Mixed Meal Tolerance Test (MMTT)
Time Frame: between baseline and 5 and 12 months after the first injection
|
between baseline and 5 and 12 months after the first injection
|
Collaborators and Investigators
Investigators
- Study Director: Anne Hildur Henriksen, MD PhD, St Olavs Hospital, Medisinsk Klinikk
- Study Director: Torstein Baade Rø, MD, Norwegian University of Science and Technology, IKOM
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GADinLADA
- 2019-002692-34 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Latent Autoimmune Diabetes in Adults
-
Abertawe Bro Morgannwg University NHS TrustNovo Nordisk A/SUnknownLatent Autoimmune Diabetes in Adults LADAUnited Kingdom
-
Children's Hospital of PhiladelphiaCompletedLatent Autoimmune Diabetes in AdultUnited States, United Kingdom
-
Diamyd Therapeutics ABCompletedLatent Autoimmune Diabetes in Adult (LADA)Sweden
-
DeveloGen Israel, Ltd.Terminated
-
Norwegian University of Science and TechnologyWithdrawn
-
University of WashingtonGlaxoSmithKline; Seattle Institute for Biomedical and Clinical ResearchCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Exerscrip...RecruitingType 1 Diabetes | Pancreatitis | Latent Autoimmune Diabetes in AdultsUnited States
-
Karolinska InstitutetNovo Nordisk A/S; The Swedish Research Council; Swedish Council for Working Life...CompletedType 2 Diabetes | Latent Autoimmune Diabetes in AdultsSweden
-
Universidad Juárez Autónoma de TabascoCompletedLatent Autoimmune DiabetesMexico
-
Jiangsu HengRui Medicine Co., Ltd.CompletedDiabetes in AdultsChina
Clinical Trials on recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel
-
Diamyd Medical ABRecruitingType 1 Diabetes MellitusCzechia, Spain, United States, Hungary, Netherlands, Estonia, Germany, Poland, Sweden